BMJ Open (Aug 2023)

Role of fatty liver in the epidemic of advanced chronic liver disease among people with HIV: protocol for the Canadian LIVEHIV multicentre prospective cohort

  • Cecilia T Costiniuk,
  • Jean-Pierre Routy,
  • Bertrand Lebouché,
  • Joseph Cox,
  • Marina B Klein,
  • Neora Pick,
  • Sharon L Walmsley,
  • Alexandra de Pokomandy,
  • Nadine Kronfli,
  • Giada Sebastiani,
  • Curtis Cooper,
  • Melanie C M Murray,
  • Colleen Price,
  • Felice Cinque,
  • Sahar Saeed,
  • Dana Kablawi,
  • Luz Ramos Ballesteros,
  • Wesal Elgretli,
  • Erica E M Moodie,
  • Ken Monteith

DOI
https://doi.org/10.1136/bmjopen-2023-076547
Journal volume & issue
Vol. 13, no. 8

Abstract

Read online

Introduction Advanced chronic liver disease (ACLD) is a major cause of death for people with HIV (PWH). While viral hepatitis coinfections are largely responsible for this trend, metabolic dysfunction-associated steatotic liver disease (MASLD) is an emerging concern for PWH. We aimed to assess the contribution of MASLD to incident ACLD in PWH.Methods and analysis This multicentre prospective observational cohort study will enrol 968 consecutive HIV monoinfected patients from four Canadian sites, excluding subjects with alcohol abuse, liver disease other than MASLD, or ACLD at baseline. Participants will be followed annually for 4 years by clinical evaluation, questionnaires, laboratory testing and Fibroscan to measure liver stiffness measurement (LSM) and controlled attenuation parameter (CAP). The primary outcome will be incidence of ACLD, defined as LSM>10 kPa, by MASLD status, defined as CAP≥285 dB/m with at least one metabolic abnormality, and to develop a score to classify PWH according to their risk of ACLD. Secondary outcomes will include health-related quality of life (HRQoL) and healthcare resource usage. Kaplan-Meier survival method and Cox proportional hazards regression will calculate the incidence and predictors of ACLD, respectively. Propensity score methods and marginal structural models will account for time-varying exposures. We will split the cohort into a training set (to develop the risk score) and a validation set (for validation of the score). HRQoL scores and healthcare resource usage will be compared by MASLD status using generalised linear mixed effects model.Ethics and dissemination This protocol has been approved by the ethics committees of all participating institutions. Written informed consent will be obtained from all study participants. The results of this study will be shared through scientific publications and public presentations to advocate for the inclusion of PWH in clinical trials of MASLD-targeted therapies and case-finding of ACLD in PWH.